Experience

• 

  ArkeaBio™

  • United States
  • Biotechnology Research
  • 1 - 100 Employee

  • Senior Lead, Clinical Development

    • Mar 2024 - Present

  • Scientist III, Vaccination + Field Trials Lead

    • Mar 2023 - Mar 2024

  • Scientist II

    • Oct 2022 - Mar 2023

• 

  Bio-Rad Laboratories

  • Boulder, Colorado

  • Senior Scientist

    • Apr 2020 - Mar 2022
    • Boulder, Colorado

    Formerly Dropworks Inc., acquired by Bio-Rad Laboratories in October 2021Bio-Rad’s Digital Biology Group is a leader in the nucleic acid quantification space, with several Droplet Digital PCR (ddPCR) workflows currently available to researchers. ddPCR workflows enable the partitioning and PCR amplification of template molecules for absolute quantification, offering improved precision and sensitivity over transitional qPCR workflows. In October 2021, Bio-Rad expanded it’s ddPCR portfolio with the acquisition of Dropworks and the Continuum platform. Continuum seeks to fully automate ddPCR, making the user workflow and reaction costs competitive with qPCR.

• 

  The Janssen Pharmaceutical Companies of Johnson & Johnson

  • United States
  • Pharmaceutical Manufacturing
  • 700 & Above Employee

  • Associate Scientist II

    • Oct 2019 - Mar 2020

    RNA & Targeted Therapeutics collaborates with Therapeutic Areas across Janssen Pharmaceuticals to develop novel synthetic modalities targeting intracellular- and tissue-specific uptake. These include nucleic acid delivery using lipid nanoparticles, antibody-drug conjugates, peptide conjugates and more.

  • Associate Scientist I

    • Feb 2018 - Oct 2019

  • Research Associate I

    • Dec 2017 - Feb 2018

• 

  Progenra, Inc.

  • Malvern, PA

  • Scientist I

    • Sep 2016 - Nov 2017
    • Malvern, PA

    Progenra seeks to discover a first-in-class small molecular drug targeting the Ubiquitin-Proteasome System across multiple therapeutic areas.

• 

  The Janssen Pharmaceutical Companies of Johnson & Johnson

  • Spring House, PA

  • Intern - Systems Pharmacology and Biomarkers

    • May 2015 - Aug 2015
    • Spring House, PA

    Systems Pharmacology and Biomarkers works with Discovery R&D at Janssen Pharmaceuticals to use a systems biology approach to identify novel targets and pathways that may be candidates for Janssen’s drug-discovery pipeline. Researchers utilize molecular data from both human and animal samples to construct in silico networks focused on various therapeutic areas, such as Asthma & COPD.